Preventing the Next Heart Attack
We’ve got your heart covered
It takes only 3 minutes to prevent the next heart attack*
CORA is a short exam that indicates a patient’s risk-level for having CAD. CORA has the potential to save the lives of millions of patients worldwide, while simultaneously decreasing health care-related costs.
Product not cleared yet by the FDA. Not available for sale in the US.
Accurate
Validated in clinical study
Easy to Use
Can be performed by any medical staff personnel in any setting
Affordable
Zero cost per exam
Fast
3-minute exam
Cost Effective
Can save millions of dollars on medical expenses
Risk-Free
Non-invasive, no radiation
Early Detection Tools Fall Short
Currently, physicians have limited front-line diagnostic tools for the early detection of coronary artery disease (CAD) - the cause of heart attacks.
CAD in Numbers
Technology
Any patient. Anytime. Anywhere.
AccuLine’s technology is based on the detection of 2 novel biomarkers in combination with AI-powered signal processing and proprietary augmented waveform display.
2 Novel Bioindicators
- Voltage Spread – inter-cycle variability of the voltage
- VCG – 3D image of the heart’s electrical activity
Augmented Data Display Proprietary novel data display technology
Advanced Signal Processing
- Improved filtering algorithms
- ML powered analysis of electric signals
Clinical Results
Significant difference between patient with and without significant CAD
About
AccuLine is a digital healthcare company, which was founded with the vision to saves the lives of millions of people worldwide, by preventing the next heart attack. AccuLine is developing CORA— a smart, accurate, and easy to use exam for the early detection of coronary artery disease.
The clinically validated CORA deploys advanced ML-powered signal processing algorithms, analyzing two bio-signals the company discovered in the heart’s electrical activity, indicating the patient’s risk of having coronary artery disease.
AccuLine has received a grant from the Israeli Innovation Authority and is a portfolio company of eHealth Ventures—founded by Maccabi Health Services, backed by Amgen, Medison Ventures, SCI (Shanghai Creation Investment), and partnered with Mayo Clinic.
Team
Led by experts to revolutionize the future of
ischemic heart disease managment
Moshe Barel
CEO & Co-Founder
X
Moshe has more than 15 years of experience in the medical device industry, having taken leadership roles within start-up companies and global corporates. Before joining AccuLine, Moshe served as CEO of Intratech Medical, where he continues to serve as an Executive Chairman today. Prior to that, Moshe served as CEO at Sanolla, VP of Strategy at NovaSight, and business unit director at Lumenis and Johnson & Johnson.
Moshe holds a BA in Economics AND Business Administration and an MSc in Business Administration – both from Tel-Aviv university. LinkedIn
Prof. Aharon Frimerman
CMO & Co-Founder
X
Aharon Frimerman, M.D, is a cardiologist and head of the catheterization laboratory unit at Hillel-Yaffe Medical Center, Israel, as well as a Professor of Cardiology at the faculty of medicine of the Technion, the Israeli Institute of Technology. Prof. Frimerman serves as a member of the editorial board at the journal of the Israel Heart Society, reviewer at the Journal of Interventional Cardiology and member of the interventional cardiology devices committee for the Israeli ministry of health. He has won several awards from the Israeli Heart Society, the Israeli ministry of health, Technion’s faculty of medicine, and Hillel-Yaffe medical center for excellence in research and in teaching. Prof. Frimerman has published dozens of scientific papers and has 9 patents under his name. Prof. Frimerman also served as an advisor to Boston Scientific, Siemens, RDC Medical, Angioslide, Sync-Rx, Elcam Medical, and Naiot Technological Center.
Benny Shani
CTO & Co-Founder
X
Benny is a veteran R&D leader with almost 40 years of experience in executive roles within numerous hi-tech organizations, in various fields. Benny started his career at the Israel Military Industries in the rocket division’s computer center. Following that Beni joined Tecnomatix as product manager, where he developed 3D computer aided process planning later implemented by several large car manufacturers as well as aerospace, energy, and industrial companies. After that, Benny served as VP of Technologies at PixelMultimedia. Following that, Benny was the co-founder and VP of R&D at New Media Communications, which was acquired by Harmonic Data Systems, where Benny was appointed as CTO.
Benny has a BSc (cum laude) and an MSc in mechanical engineering, both from the Technion, the Israeli Institute of Technology, and he holds 4 patents under his name. LinkedIn
Prof. Shai Revzen
CSO & Co-Founder
X
Shai Revzen is an Associate Professor in the departments of Electrical Engineering and Computer Science at the University of Michigan, Ann Arbor, and a founding member of the Michigan Robotics Institute. Prof. Revzen holds a PhD in biomechanics from the University of California, Berkeley, an MSc in computer science from the Hebrew University in Jerusalem and did his post-doctoral in University of Pennsylvania. He heads the BIRDS Lab, which focuses on the crucial role of mechanics in robot motion. Prof. Revzen has more than 100 scientific publications in top engineering, biology and applied mathematics journals, and several registered patents. LinkedIn
Preventing the Next Heart Attack
info@acculine-medical.com+972-3-5284-803
2 Rafael-Eitan St.
Petach-Tikva, 4906508
Israel